Reading PFE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PFE free→Reading PFE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PFE free→QuarterlyIQ Insights · PFE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Other Events On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 2025, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of November 7, 2025, by and among the Company, Metsera and Mayfair Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (as a…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Cost Associated with Exit or Disposal Activities On April 29, 2025, Pfizer announced approximately $1.2 billion of additional anticipated savings associated with its ongoing cost realignment program (the “Realigning Our Cost Base Program” or the “Program”) expected to be achieved by the end of 2027, designed to further reduce costs primarily in selling, information and administrative expenses (“SI&A”) driven in large part by enhanced digital enablement, including automation and artificial int…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Mr. Buckley to the Board of Directors On October 10, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Mortimer J. Buckley to serve as a member of the Company’s Board, effective immediately. In addition, he was elected to the Governance & Sustainability Committee and the Audit Committee of the Board. Mr.…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Modifications to Five-Year Total Shareholder Return Units and Performance Share Awards As disclosed in
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 9, 2024, Pfizer Inc. (the "Company") announced that it is beginning the process of finding a successor for Dr. Mikael Dolsten, the Company’s Chief Scientific Officer and President, Pfizer Research & Development after his more than 15-year distinguished career with the Company. The Company has initiated an external search for a new Chief Sci…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Election of Mr. Taraporevala to the Board of Directors On June 27, 2024, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Cyrus Taraporevala to serve as a member of the Company’s Board, effective immediately. In addition, he was appointed to and will join the Audit Committee and the Compensation Committee of the Board. Mr…
Costs Associated with Exit or Disposal Activities In the second quarter of 2024, Pfizer announced it is launching a multi-year program to reduce our cost of goods sold. This cost reduction program (the “program”) will span multiple years, and is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. Given the complexity in manufacturing and longer lead times required to make changes, this program will be a multi-phased effort. The first ph…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
Completion of Acquisition or Disposition of Assets. Pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of March 12, 2023, by and among Pfizer Inc., a Delaware corporation (“ Pfizer ”), Aris Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pfizer (“ Merger Sub ”), and Seagen Inc., a Delaware corporation (“ Seagen ”), Merger Sub was merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of…
Completion of Acquisition or Disposition of Assets. Pursuant to an Agreement and Plan of Merger (the “ Merger Agreement ”), dated as of March 12, 2023, by and among Pfizer Inc., a Delaware corporation (“ Pfizer ”), Aris Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Pfizer (“ Merger Sub ”), and Seagen Inc., a Delaware corporation (“ Seagen ”), Merger Sub was merged with and into Seagen (the “ Merger ”), with Seagen surviving the Merger as a wholly owned subsidiary of…
Regulation FD Disclosure. As previously disclosed, on March 12, 2023, Pfizer entered into an Agreement and Plan of Merger with Seagen, pursuant to which Pfizer will acquire Seagen through a merger (the “Merger”). On December 12, 2023, Pfizer announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired on December 11, 2023. A copy of the press release is attached as Exhibit 99.1 hereto. Pfizer and Seagen have now received all required re…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 12, 2023, Pfizer Inc. (“Pfizer” or “the Company”) announced that given the size and geographic scope of Pfizer’s commercial operations and the anticipated close of the acquisition of Seagen Inc. (“Seagen”), the following changes to its commercial operations will become effective on January 1, 2024. Pfizer will create an end-to-end busin…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expr…
Costs Associated with Exit or Disposal Activities. In the fourth quarter of 2023, Pfizer announced that, to realign Pfizer’s costs with its longer-term revenue expectations, Pfizer launched a multi-year, enterprise-wide cost realignment program (the “ Cost Realignment Program ”). The Cost Realignment Program is expected to deliver targeted savings of at least $3.5 billion, of which $1.0 billion is expected to be realized in 2023 and an additional $2.5 billion is expected to be realized in 202…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or the Securities Act of 1933, as amended (the “ Securities Act” ), regardless of any general incorporation language in any s…
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expr…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.